Time is money, and in the case of Pasithea Therapeutics Corp., a biotechnology company specializing in treatments for Central Nervous System disorders and other diseases, the time to invest is now. With a strong buy consensus from analysts and a valuation market value of $7.25, the stock is currently undervalued compared to its real value of $3.95. The company's lead product candidate, PAS-004, is a next-generation MEK inhibitor designed for use in anti-depression clinics, showing promising potential. The stock's day typical price is $7.25, with a possible upside price of $12.4, indicating a significant potential for growth. The rate of daily change stands at 1.01, and the period momentum indicator is at 0.1, both suggesting a positive trend. The company's fiscal year ends in December, providing ample time for investors to seize this opportunity. With a valuation hype value of $7.27, Pasithea Therapeutics Corp. is a stock to watch in the healthcare and biotechnology sector. We primarily analyze the price patterns of Pasithea Therapeutics Corp (US Stock: KTTA) and their correlation with various microeconomic environments and drivers. We use predictive analytics to develop daily price indicators for Pasithea and compare them with related drivers. Today, we'll discuss Pasithea Therapeutics and explain why we remain confident in expecting a recovery.
The successful prediction of Pasithea Therapeutics
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Pasithea Therapeutics Corp, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Pasithea Therapeutics based on Pasithea Therapeutics hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Pasithea Therapeutics's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Pasithea Therapeutics's related companies.
Use Technical Analysis to project Pasithea expected Price
Pasithea Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Pasithea Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Pasithea Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Pasithea Therapeutics Gross Profit
Pasithea Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Pasithea Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Pasithea Therapeutics Gross Profit growth over the last 10 years. Please check Pasithea Therapeutics'
gross profit and other
fundamental indicators for more details.
Detailed Perspective On Pasithea Therapeutics
The company reported the previous year's revenue of 486.56
K. Net Loss for the year was (16.03
M) with loss before overhead, payroll, taxes, and interest of (2.21
K).
Total Revenue Breakdown
Pasithea Therapeutics' Total Revenue is increasing over the years with slightly volatile fluctuation. Total Revenue is expected to dwindle to about 362.3
K. Total Revenue usually refers to the total amount of income generated by the sale of goods or services related to the company's primary operations. At present, Pasithea Therapeutics' Total Revenue is projected to increase significantly based on the last few years of reporting.
| 2010 | 15,062 |
| 2022 | 486,559 |
| 2023 | 559,543 |
| 2024 | 362,332 |
As the renowned investor Warren Buffet once said, "Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble." This wisdom is particularly relevant when considering the potential of Pasithea Therapeutics Corp, a biotechnology company with a focus on Central Nervous System disorders and other diseases. With a market capitalization of $7.55M and a robust current ratio of 51.17X, the company demonstrates a strong financial position. Despite the industry's inherent risks, as evidenced by a 36.91% probability of bankruptcy, the company's potential upside of 8.95 suggests a promising future. Furthermore, the company's shares are largely held by institutions, accounting for 23.88% of ownership, indicating a vote of confidence from savvy investors.
Pasithea technical analysis suggests possible bounce-back
Despite Pasithea Therapeutics Corp stock's current kurtosis rising to -0.04, suggesting a potential price drop, our
technical analysis indicates a possible rebound. This is typical in the fluctuating stock market, where negative kurtosis can often signal a recovery. Investors should monitor the stock's performance and market trends closely, as the current situation may offer a buying opportunity. Pasithea Therapeutics Corp shows very low volatility with a skewness of 0.44 and kurtosis of -0.04. Understanding
market volatility trends can help investors time their investments. Using volatility indicators correctly allows traders to gauge Pasithea Therapeutics' stock risk against market volatility during both bullish and bearish trends. The increased volatility of bear markets can directly affect
Pasithea Therapeutics' stock price and stress investors as they see their shares' value decrease, often prompting portfolio rebalancing.
In light of the
current market conditions, Pasithea Therapeutics Corp. presents a compelling investment opportunity. The company, which operates in the biotechnology sector with a focus on Central Nervous System disorders and other diseases, has a strong product pipeline led by its candidate PAS-004. The company's valuation real value stands at
3.95, while the naive expected forecast value is at
7.7, indicating a potential upside. The analyst overall consensus for the stock is a 'Strong Buy', with an estimated target price value of 2, and a possible upside price of 12.4. Given these factors, now may be an opportune time to consider investing in Pasithea Therapeutics Corp. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Pasithea Therapeutics Corp. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]